Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 51,425 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at $61,220,021.39. The trade was a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Christopher Richard Anzalone also recently made the following trade(s):

• On Tuesday, March 4th, Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66.
• On Thursday, January 2nd, Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00.
• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Trading Up 1.6 %

Shares of ARWR opened at $15.60 on Tuesday. The business’s 50-day moving average price is $18.93 and its 200 day moving average price is $20.11. The stock has a market capitalization of $2.14 billion, a P/E ratio of -3.02 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $14.23 and a 1-year high of $30.41. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Ratings Changes

ARWR has been the topic of a number of recent analyst reports. Sanford C. Bernstein lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. Piper Sandler cut their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Finally, Citigroup cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $41.44.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. World Investment Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 3.8% during the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after buying an additional 700 shares during the last quarter. Xponance Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 4.5% during the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock valued at $327,000 after buying an additional 744 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock valued at $714,000 after buying an additional 803 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Arrowhead Pharmaceuticals by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock valued at $1,199,000 after buying an additional 886 shares during the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 10.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,195 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.